semaglutide body composition Weight loss and after compounded treatment in a real world setting - Chun - 2025 - Diabetes, Obesity and Metabolism Frontiers | Transforming body composition

BMI body mass index DPP dipeptidyl peptidase DPL DPP4-like protein FAP fibroblast activation protein GIP glucose-dependent insulinotropic polypeptide GLP-1 glucagon-like peptide-1 QPP quiescent cell proline dipeptidase SDF-1 Stromal cell-derived factor-1 T2DM type 2 diabetes mellitus

Even small amounts of concentrated sugar can trigger symptoms in sensitive patients

46 Tirzepatide also improved sleep-associated patient-reported outcomes

Neurotox Res 43 , 27 (2025)

The treatment follows a gradual dose-escalation approach and is designed for long-term use as part of a comprehensive medical weight management plan

The most common issues were nausea (20% to 47% depending on dose), followed by constipation, diarrhea, and abdominal discomfort